Traci DeVito

home / authors / traci-devito

Articles

FDA Approves Two New Indications and Dosage Form for Pembrolizumab

FDA Approves Two New Indications and Dosage Form for Pembrolizumab

Traci DeVito;Naveed Saleh, MD, MS
May 14th 2019

In this installment of Oncology Drug Updates, updates to FDA approvals for pembrolizumab in the treatment of lung cancer and RCC are highlighted.

Key Advances in Oncology, 2018

Key Advances in Oncology, 2018

Traci DeVito;Jennifer Leavitt, MS;Naveed Saleh, MD, MS
January 17th 2019

Our team reviews the most important advances in oncology in 2018, including those in breast cancer, hematologic cancers, lung cancer, immunotherapy, and more.

Oncology Conference Highlights, Q4

Oncology Conference Highlights, Q4

Jennifer Leavitt, MS;Traci DeVito;Naveed Saleh, MD, MS
January 17th 2019

Our team reviews 2018 conference highlights in oncology care, including studies from ASH, SABCS, and SIO.

The Long-Term Outlook for Mogamulizumab in Previously Treated Cutaneous T-Cell Lymphoma

The Long-Term Outlook for Mogamulizumab in Previously Treated Cutaneous T-Cell Lymphoma

Traci DeVito
December 6th 2018

The results of a follow-up analysis to the phase III MAVORIC study were presented at the ASH 2018 Annual Meeting & Exposition.

Biosimilars: New Avenues for the Practicing Oncologist Treating Breast Cancer

Biosimilars: New Avenues for the Practicing Oncologist Treating Breast Cancer

Traci DeVito
October 25th 2018

Research presented this week at ESMO studied the efficacy of biosimilars to trastuzumab compared with the reference product in breast cancer.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
A 23-Year-Old Male With Right Leg Pain
Published: April 26th 2018 | Updated: July 25th 2025
A 23-Year-Old Male With Right Leg Pain